The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

Leukemia

Volumn 25, Issue 7, 2011, Pages 1182-1188

  Asano, J ^a   Nakano, A ^a   Oda, A ^a   Amou, H ^a   Hiasa, M ^b   Takeuchi, K ^a   Miki, H ^a   Nakamura, S ^a   Harada, T ^a   Fujii, S ^a   Kagawa, K ^a   Endo, I ^a   Yata, K ^a   Sakai, A ^c   Ozaki, S ^d   Matsumoto, T ^a   Abe, M ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

bone marrow stromal cell; IL 6; myeloma; osteoclast; Pim 2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 (4 PROPOXYBENZYLIDENE)THIAZOLIDINE 2,4 DIONE; APRIL PROTEIN; B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 6; MYC PROTEIN; PIM 2 PROTEIN; PROTEIN MCL 1; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SMALL INTERFERING RNA; SOMATOMEDIN C; STAT3 PROTEIN; THIAZOLIDINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE SILENCING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL DIFFERENTIATION; CELL LINE; CHROMONES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MORPHOLINES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NF-KAPPA B; OSTEOCLASTS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 79960240251     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.60     Document Type: Article

References (20)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374: 324-339.
2. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010; 28: 244-250.
3. Matsumoto T, Abe M. Bone destruction in multiple myeloma. Ann N Y Acad Sci 2006; 1068: 319-326. (Pubitemid 43824163)
4. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-2491. (Pubitemid 39331851)
5. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al. Cancer and the microenvironment: myelomaosteoclast interactions as a model. Cancer Res 2004; 64: 2016-2023. (Pubitemid 38339448)
6. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
7. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004; 103: 689-694. (Pubitemid 38140105)
8. Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148-3157. (Pubitemid 38451693)
9. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005; 106: 1021-1030. (Pubitemid 41076449)
10. Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H et al. BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia 2006; 20: 1313-1315. (Pubitemid 43905843)
11. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105: 4477-4483. (Pubitemid 40720797)
12. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100: 2195-2202. (Pubitemid 35001256)
13. Hiasa M, Abe M, Nakano A, Oda A, Amou H, Kido S et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009; 114: 4517-4526.
14. Menu E, van Valckenborgh E, van Camp B, Vanderkerken K. The role of the insulin-like growth factor 1 receptor axis in multiple myeloma. Arch Physiol Biochem 2009; 115: 49-57.
15. Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy Jr JD, Barlogie B et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009; 113: 4614-4626.
16. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009; 52: 74-86.
17. Beharry Z, Zemskova M, Mahajan S, Zhang F, Ma J, Xia Z et al. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther 2009; 8: 1473-1483.
18. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17: 1841-1854. (Pubitemid 36944562)
19. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107: 4053-4062. (Pubitemid 43726814)
20. McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res 2009; 69: 5835-5842.